The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer syntheses that challenge innovators' timely readiness for the Clinic.
Sponsored by:
On Demand Webinars
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
White Papers
AI-ENABLED PHARMACEUTICAL COCRYSTAL SCREENING
This white paper from Lonza and the American Chemical Society explains how AI-enabled cocrystal screening can help pharmaceutical companies identify promising solid forms of APIs earlier.
AI- and Model-Based Tools to Streamline Drug Development
This Lonza resource explains how AI, high-throughput experimentation (HTE), and model-based tools can streamline small-molecule drug development.
Bringing novel ADC formats into the clinic
This white paper from Lonza explains how next-generation antibody-drug conjugates (ADCs), especially antibody-oligonucleotide conjugates (AOCs), are expanding bioconjugate
Advancing ADCs: From concept to commercialization
This Lonza white paper explains how ADC development has evolved and how end-to-end technologies and manufacturing capabilities can help accelerate ADCs from concept to commercialization.
From Discovery to Patients: an Integrated Service for ADC Development by Lonza and Synaffix
This Lonza white paper explains how Synaffix technology and Lonza’s integrated ADC development services can help drug developers move antibody-drug conjugates (ADCs
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Precision in miniature: optimizing multiparticulate formulations for pediatric oncology
This white paper details a collaborative effort between Lonza’s Bend, OR site and Pfizer’s Groton, CT team to develop a robust commercial control strategy for a pediatric dosage form for crizotinib (Xalkori) in a material sparing fashion.
Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates
Bioconjugates are no longer just for cancer therapies. This paper reveals how innovative advancements are opening up a new world of possibilities, from muscle disorders to inflammatory diseases.
Design Smarter Dose Strategies for Adaptive Clinical Trials
In an era of precision medicine and adaptive clinical trial designs, dose flexibility is no longer optional—it’s essential. From preclinical development to commercialization, the ability to scale, modify, and tailor dose strengths is key to meeting regulatory expectations and optimizing patient-centered therapies.
Optimizing Excipients for Biologic Therapies Delivered via Inhalation
The shift toward biologics delivered via the respiratory route is accelerating—and with it comes the need for precision in excipient selection. Whether in nebulized liquids or dry powder inhalers, biologics demand tailored formulation strategies to ensure safety, stability, and therapeutic effectiveness.
Accelerate Commercial Tech Transfers for Oral Solid Dosage (OSD) Success
Efficient tech transfer is critical to the success of every Oral Solid Dosage (OSD) product—especially when transitioning from development to full-scale commercial manufacturing.